RARA CRAFT DATABASE for FDA Medical Devices
510(k)K193573

FDA DEVICE FACTS

Biogel Skinsense Indicator Underglove, Biogel PI Ultratouch, Biogel PI Indicator Underglove, Biogel PI, Biogel PI Micro

Molnlycke Health Care Us, LLC

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

DECISION DATEApril 10, 2020PRODUCT CODEKGO

Indications for use

Biogel® Skinsense® Indicator® Underglove tested for use with chemotherapy agents

A powder-free, sterile, surgeon’s glove is a disposable device made of non -latex that is intended to be worn on the hands, usually in surgical settings, to provide a barrier against potentially infectious materials and other contaminants.

In addition, these gloves were tested for use with chemotherapy drugs in accordance with ASTM D6978 Standard Practice for Assessment of Resistance of Medical Gloves to Permeation by Chemotherapy Drugs:

Drug and Concentration Breakthrough detection time in minutes (0.01µg/cm2/mins) Bleomycin 15 mg/ml >240 Busulfan 6 mg/ml >240 Carmustine 3.3 mg/ml 6.6 Cisplatin 1.0 mg/ml >240 Cyclophosphamide (Cytoxan) 20 mg/ml >240 Cytarabine 100 mg/ml >240 Dacarbazine (DTIC) 10 mg/ml >240 Doxorubicin Hydrochloride 2 mg/ml >240 Ellence 2 mg/ml >240 Etoposide (Toposar) 20 mg/ml >240 Fludarabine 25 mg/ml >240 Fluorouracil 50 mg/ml >240 Idarubicin 1 mg/ml >240 Ifosfamide 50 mg/ml >240 Mechlorethamine HCl 1 mg/ml >240 Melphalan 5 mg/ml >240 Methotrexate 25 mg/ml >240

Mitomycin C 0.5 mg/ml >240 Mitoxantrone 2 mg/ml >240 Paclitaxel (Taxol) 6 mg/ml >240 Paraplatin 10 mg/ml >240 Rituximab 10 mg/ml >240 Thiotepa 10 mg/ml 16.9 Vincristine Sulfate 1 mg/ml >240

Please note that Carmustine (3.3 mg/ml) and Thiotepa (10 mg/ml) have much lower permeation times compared to other chemotherapy drugs:

 Carmustine (3.3 mg/ml) has a minimum breakthrough time of 6.6 minutes.  Thiotepa (10 mg/ml) has a minimum breakthrough time of 16.9 minutes

Biogel® PI Micro tested for use with chemotherapy agents

The Biogel PI Micro Surgical Glove is a disposable device made of polyisoprene material that is intended to be worn on the hands, usually in surgical settings, to provide a barrier against potentially infectious materials and other contaminants.

In addition, these gloves were tested for use with chemotherapy drugs in accordance with ASTM D6978 Standard Practice for Assessment of Resistance of Medical Gloves to Permeation by Chemotherapy Drugs:

Drug and Concentration Breakthrough detection time in minutes (0.01µg/cm2/mins) Bleomycin 15 mg/ml >240 Busulfan 6 mg/ml >240 Carmustine 3.3 mg/ml 10.0 Cisplatin 1.0 mg/ml >240 Cyclophosphamide (Cytoxan) 20 mg/ml >240 Cytarabine 100 mg/ml >240 Dacarbazine (DTIC) 10 mg/ml >240 Doxorubicin Hydrochloride 2 mg/ml >240 Ellence 2 mg/ml >240 Etoposide (Toposar) 20 mg/ml >240 Fludarabine 25 mg/ml >240 Fluorouracil 50 mg/ml >240 Idarubicin 1 mg/ml >240 Ifosfamide 50 mg/ml >240 Mechlorethamine HCl 1 mg/ml >240 Melphalan 5 mg/ml >240 Methotrexate 25 mg/ml >240

Mitomycin C 0.5 mg/ml >240 Mitoxantrone 2 mg/ml >240 Paclitaxel (Taxol) 6 mg/ml >240 Paraplatin 10 mg/ml >240 Rituximab 10 mg/ml >240 Thiotepa 10 mg/ml 20.3 Vincristine Sulfate 1 mg/ml >240

Please note that Carmustine (3.3 mg/ml) and Thiotepa (10 mg/ml) have much lower permeation times compared to other chemotherapy drugs:

 Carmustine (3.3 mg/ml) has a minimum breakthrough time of 10.0 minutes.  Thiotepa (10 mg/ml) has a minimum breakthrough time of 20.3 minutes

Biogel® PI UltraTouch® tested for use with chemotherapy agents

A powder-free sterile surgeon’s glove is a disposable device made of polyisoprene that is intended to be worn on the hands, usually in surgical settings, to provide a barrier against potentially infectious materials and other contaminants.

In addition, these gloves were tes ted for use with chemotherapy drugs in accordance with ASTM D6978 Standard Practice for Assessment of Resistance of Medical Gloves to Permeation by Chemotherapy Drugs:

Drug and Concentration Breakthrough detection time in minutes (0.01µg/cm2/mins) Bleomycin 15 mg/ml >240 Busulfan 6 mg/ml >240 Carmustine 3.3 mg/ml 24.2 Cisplatin 1.0 mg/ml >240 Cyclophosphamide (Cytoxan) 20 mg/ml >240 Cytarabine 100 mg/ml >240 Dacarbazine (DTIC) 10 mg/ml >240 Doxorubicin Hydrochloride 2 mg/ml >240 Ellence 2 mg/ml >240 Etoposide (Toposar) 20 mg/ml >240 Fludarabine 25 mg/ml >240 Fluorouracil 50 mg/ml >240 Idarubicin 1 mg/ml >240 Ifosfamide 50 mg/ml >240 Mechlorethamine HCl 1 mg/ml >240 Melphalan 5 mg/ml >240 Methotrexate 25 mg/ml >240

Mitomycin C 0.5 mg/ml >240 Mitoxantrone 2 mg/ml >240 Paclitaxel (Taxol) 6 mg/ml >240 Paraplatin 10 mg/ml >240 Rituximab 10 mg/ml >240 Thiotepa 10 mg/ml 17.9 Vincristine Sulfate 1 mg/ml >240

Please note that Carmustine (3.3 mg/ml) and Thiotepa (10 mg/ml) have much lower permeation times compared to other chemotherapy drugs:

 Carmustine (BCNU) (3.3 mg/ml) has a minimum breakthrough time of 24.2 minutes.  Thiotepa (10 mg/ml) has a minimum breakthrough time of 17.9 minutes

Biogel® PI tested for use with chemotherapy agents

A powder-free sterile surgeon’s glove is a disposable device made of polyisoprene that is intended to be worn on the hands, usually in surgical settings, to provide a barrier against potentially infectious materials and other contaminants.

In addition, these gloves were tested for use with chemotherapy drugs in accordance with ASTM D6978 Standard Practice for Assessment of Resistance of Medical Gloves to Permeation by Chemotherapy Drugs:

Drug and Concentration Breakthrough detection time in minutes (0.01µg/cm2/mins) Bleomycin 15 mg/ml >240 Busulfan 6 mg/ml >240 Carmustine 3.3 mg/ml 26.7 Cisplatin 1.0 mg/ml >240 Cyclophosphamide (Cytoxan) 20 mg/ml >240 Cytarabine 100 mg/ml >240 Dacarbazine (DTIC) 10 mg/ml >240 Doxorubicin Hydrochloride 2 mg/ml >240 Ellence 2 mg/ml >240 Etoposide (Toposar) 20 mg/ml >240 Fludarabine 25 mg/ml >240 Fluorouracil 50 mg/ml >240 Idarubicin 1 mg/ml >240 Ifosfamide 50 mg/ml >240 Mechlorethamine HCl 1 mg/ml >240 Melphalan 5 mg/ml >240 Methotrexate 25 mg/ml >240

Mitomycin C 0.5 mg/ml >240 Mitoxantrone 2 mg/ml >240 Paclitaxel (Taxol) 6 mg/ml >240 Paraplatin 10 mg/ml >240 Rituximab 10 mg/ml >240 Thiotepa 10 mg/ml 28.7 Vincristine Sulfate 1 mg/ml >240

Please note that Carmustine (3.3 mg/ml) and Thiotepa (10 mg/ml) have much lower permeation times compared to other chemotherapy drugs:

 Carmustine (BCNU) (3.3 mg/ml) has a minimum breakthrough time of 26.7 minutes.  Thiotepa (10 mg/ml) has a minimum breakthrough time of 28.7 minutes

Biogel® PI Indicator® Underglove tested for use with chemotherapy agents

The Skinsense polyisoprene underglove is a disposable device made of polyisoprene that is intended to be worn on the hands, usually in surgical settings, to provide a barrier against potentially infectious materials and other contaminants.

In addition, these gloves were tested for use with chemoth erapy drugs in accordance with ASTM D6978 Standard Practice for Assessment of Resistance of Medical Gloves to Permeation by Chemotherapy Drugs:

Drug and Concentration Breakthrough detection time in minutes (0.01µg/cm2/mins) Bleomycin 15 mg/ml >240 Busulfan 6 mg/ml >240 Carmustine 3.3 mg/ml 17.3 Cisplatin 1.0 mg/ml >240 Cyclophosphamide (Cytoxan) 20 mg/ml >240 Cytarabine 100 mg/ml >240 Dacarbazine (DTIC) 10 mg/ml >240 Doxorubicin Hydrochloride 2 mg/ml >240 Ellence 2 mg/ml >240 Etoposide (Toposar) 20 mg/ml >240 Fludarabine 25 mg/ml >240 Fluorouracil 50 mg/ml >240 Idarubicin 1 mg/ml >240 Ifosfamide 50 mg/ml >240 Mechlorethamine HCl 1 mg/ml >240 Melphalan 5 mg/ml >240 Methotrexate 25 mg/ml >240

Mitomycin C 0.5 mg/ml >240 Mitoxantrone 2 mg/ml >240 Paclitaxel (Taxol) 6 mg/ml >240 Paraplatin 10 mg/ml >240 Rituximab 10 mg/ml >240 Thiotepa 10 mg/ml 24.1 Vincristine Sulfate 1 mg/ml >240

Please note that Carmustine (3.3 mg/ml) and Thiotepa (10 mg/ml) have much lower permeation times compared to other chemotherapy drugs:

 Carmustine (BCNU) (3.3 mg/ml) has a minimum breakthrough time of 17.3 minutes.  Thiotepa (10 mg/ml) has a minimum breakthrough time of 24.1 minutes

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: August 24, 2026